Prescribing Information can be found at the bottom of this page.
STRENGTH FOR ACTINIC KERATOSIS, TOLERABILITY FOR PATIENTS1,2
KLISYRI® (Tirbanibulin) is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.1
1. About KLISYRI®
KLISYRI® (tirbanibulin) is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.1
NOVEL MoA FOR THE TREATMENT OF AK
Inhibition of tubulin polymerisation causing
apoptosis1,3-5
COMPLETE AK CLEARANCE
At day 57, patients treated with tirbanibulin had
statistically significantly higher complete clearance rates than patients treated with vehicle (p<0.0001)2
GENERALLY WELL-TOLERATED FIELD THERAPY
All different types of severe local skin reactions (LSRs) had an incidence < 10%2
A NOVEL TREATMENT EXPERIENCE FOR AK PATIENTS
2. How to use KLISYRI®: Dosing & administration
CONVENIENT SHORT TREATMENT COURSE FOR YOUR PATIENTS
Once daily dose for only 5 consecutive days1,6-10
Only 5 days
KLISYRI® HAS DEMONSTRATED 99% treatment COMPLIANCE IN CLINICAL TRIALS2
3. Patient Support
A patient brochure which outlines AK and KLISYRI® is available
A dedicated brochure to support your patients in their journey with KLISYRI®
References
1. KLISYRI® PI. KLISYRI® SmPC. Almirall. 2. Blauvelt A, et al. Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384(6):512-520. 3. Niu L, et al. Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of ß-tubulin explains KXO1’s low clinical toxicity. J Biol Chem. 2019;294(48):18099-18108. 4. Blauvelt A, et al. Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling, for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies. SKIN The Journal of Cutaneous Medicine. 2020; 4(5), s63. 5. Kempers S, et al. Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results. J Drugs Dermatol. 2020;19(11):1093-1100. 6. Efudix SmPC. 7. Aldara SmPC. 8. Zyclara SmPC. 9. Actikerall SmPC. 10. Solaraze SmPC.
1. KLISYRI® PI. KLISYRI® SmPC. Almirall. 2. Blauvelt A, et al. Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384(6):512-520. 3. Niu L, et al. Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of ß-tubulin explains KXO1’s low clinical toxicity. J Biol Chem. 2019;294(48):18099-18108. 4. Blauvelt A, et al. Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling, for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies. SKIN The Journal of Cutaneous Medicine. 2020; 4(5), s63. 5. Kempers S, et al. Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results. J Drugs Dermatol. 2020;19(11):1093-1100. 6. Efudix SmPC. 7. Aldara SmPC. 8. Zyclara SmPC. 9. Actikerall SmPC. 10. Solaraze SmPC.
UK-ILU-2100106 September 2021